Neurocrine Biosciences announced new clinician-survey data on INGREZZA capsules showing functional impact in patients with mild tardive dyskinesia, presented at the APA 2026 meeting. The update is incremental and supportive of the product narrative, but no sales figures, trial results, or regulatory changes were disclosed. The news is likely to have limited near-term market impact.
Neurocrine Biosciences announced new clinician-survey data on INGREZZA capsules showing functional impact in patients with mild tardive dyskinesia, presented at the APA 2026 meeting. The update is incremental and supportive of the product narrative, but no sales figures, trial results, or regulatory changes were disclosed. The news is likely to have limited near-term market impact.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
